"Hepcidins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Forms of hepcidin, a cationic amphipathic peptide synthesized in the liver as a prepropeptide which is first processed into prohepcidin and then into the biologically active hepcidin forms, including in human the 20-, 22-, and 25-amino acid residue peptide forms. Hepcidin acts as a homeostatic regulators of iron metabolism and also possesses antimicrobial activity.
| Descriptor ID |
D064451
|
| MeSH Number(s) |
D12.776.494.249 D12.776.543.695.054.425
|
| Concept/Terms |
Hepcidins- Hepcidins
- Liver-Expressed Antimicrobial Peptide
- Antimicrobial Peptide, Liver-Expressed
- Liver Expressed Antimicrobial Peptide
- Peptide, Liver-Expressed Antimicrobial
- Hepcidin
|
Below are MeSH descriptors whose meaning is more general than "Hepcidins".
Below are MeSH descriptors whose meaning is more specific than "Hepcidins".
This graph shows the total number of publications written about "Hepcidins" by people in this website by year, and whether "Hepcidins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 2 | 4 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepcidins" by people in Profiles.
-
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22; 390(8):723-735.
-
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Dec; 8(12):1118-1128.
-
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.
-
Structural basis of ferroportin inhibition by minihepcidin PR73. PLoS Biol. 2023 01; 21(1):e3001936.
-
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia. Curr Hematol Malig Rep. 2022 10; 17(5):155-169.
-
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
-
Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Am J Clin Nutr. 2021 10 04; 114(4):1408-1417.
-
Structural basis of ion transport and inhibition in ferroportin. Nat Commun. 2020 11 10; 11(1):5686.
-
Iron supplementation in infants: a reflection on hepcidin and fractional iron absorption. Am J Clin Nutr. 2020 10 01; 112(4):909-910.
-
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020 09 22; 4(18):4282-4291.